- Issuer ticker
-
ANTX
- Reported as of
-
31 Oct 2022
- Net transaction value
-
-$64,625
- SEC form
-
4
- Accepted by SEC
-
02 Nov 2022, 20:52:11 UTC
Filing notes and source
Key filing fact
Eric Easom filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 02 Nov 2022.
Key facts
- This page summarizes Eric Easom's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Nov 2022, 20:52.
Change
- Previous filing in this sequence was filed on 28 Oct 2022.
- Current net transaction value: -$64,625.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANTX
transaction
Common Stock
Sale
- Transaction value
- -$41,363
- Shares
- -2,688
- Change %
- -29%
- Price
-
$15.39
- Shares after
- 6,451
- Date
- 31 Oct 2022
- Ownership
- Direct
- Footnotes
- F1
ANTX
transaction
Common Stock
Sale
- Transaction value
- -$23,263
- Shares
- -1,544
- Change %
- -24%
- Price
-
$15.07
- Shares after
- 4,907
- Date
- 02 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote